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Objectives: Atrial ﬁbrillation is closely associated with cardioembolic stroke. Until recently, warfarin has been
the gold standard for the treatment of atrial ﬁbrillation. Since 2010 the United States Food and Drug
Administration has approved three new agents for anticoagulation in patients with atrial ﬁbrillation. The
purpose of this case report is to discuss some of the practical implications for using these agents.
Methods: A patient taking apixaban presented with a spontaneous cerebellar hemorrhage. While the patient
was initially considered a candidate for surgical intervention, the lack of literature addressing surgical
intervention in patients on novel anticoagulation clouded the clinical decision-making. The patient was
ultimately managed with administration of activated prothrombin complex concentrate, blood pressure
control, frequent clinical assessments and airway protection. The patient did not undergo craniotomy for
hematoma evacuation.
Conclusions: Recent FDA approval of several novel oral anticoagulants for use in patients with atrial ﬁbrillation
has resulted in a signiﬁcant number of patients formerly treated with warfarin being switched to these newer
agents. There remains a lack of clear guidelines for the management of hemorrhagic complications. This case
report describes one management strategy and highlights the paucity of current evidence to support critical
clinical decisions.
© 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).IntroductionIn 2010, dabigatran (Pradaxa) became the ﬁrst novel oral
anti-coagulant (NOAC) approved in the United States followed by
rivaroxaban (Xarelto) in 2011 and apixaban (Eliquis) in 2012. The
introduction of each of these agents was supported by a randomized
clinical trial: RE-LY for dabigatran, ROCKET-AF for rivaroxaban, and
ARISTOTLE for apixaban [1–3]. With respect to efﬁcacy in preventing
ischemic stroke and rate of systemic hemorrhagic complications, each
trial reported their respective NOAC as non-inferior to the current
gold standard, warfarin.
Since their approval, many governing bodies in organized
medicine, e.g. the American Academy of Neurology, now encourage
the use of the novel agents over warfarin [4] and many physicians
began prescribing these NOACs. Since their introduction into the
American pharmacological armamentarium there have been an
increasing number of publications reporting hemorrhagic complica-
tions and urging caution when using NOACs [4–6]. We present one
such hemorrhagic complication and discuss several salient aspects
of NOACs.urgery, FOT 1030, 1720 2nd
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A patient presented to the emergency department after develop-
ing acute onset dizziness, nausea and somnolence. Blood pressurewas
190/93 mm Hg and physical exam revealed a somnolent, yet
arousable individual. The Glasgow coma score (GCS) was 14. The
initial NIHSS was 4 (2— nystagmus on right lateral gaze, 2— ataxia on
left ﬁnger–nose–ﬁnger). Initial non-contrast head computerized
tomography (CT) (Fig. 1) revealed a left cerebellar intra-parenchymal
hemorrhage measuring 3.3 cm × 3.6 cm extending into the fourth
ventricle without acute hydrocephalus.
Past medical history was signiﬁcant for coronary artery disease,
hypertension, sick sinus syndrome status post implanted pacemaker
and atrial ﬁbrillation. After several years of compliant anticoagulation
with warfarin, the patient had been switched to apixaban 5 mg
approximately 10 months prior to presentation. Initial laboratory
values included platelets 152,000 per microliter (reference range (RR)
150,000–400,000 per microliter), partial thromboplastin time (PTT)
34 seconds (RR 25–35 seconds), anti-Xa abnormal, consistent with
drug in the plasma, and prothrombin time of 15 seconds (RR:
12–14 seconds).
At the recommendation of Hematology and Transfusion Medicine,
a single weight-based dose of Factor Eight Inhibitor Bypass Activity
(FEIBA or Anti-Inhibitor Coagulant Complex) was administered
on arrival to the NICU. Blood pressure was controlled using a
nicardipine infusion titrated for a goal systolic blood pressure less
than 160 mm Hg.nder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Fig. 1. Initial head CT.
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NIHSS 6 (1 LOC, 1 orientation, 2 nystagmus, 2 ataxia) with a
diminished gag reﬂex. The patient was intubated for anticipated
need for airway protection.
Although the clinical situation would often dictate neurosurgical
intervention, the patient was felt to be at high risk for intracranial
surgery due to limited data on reversal of apixaban and an expectant
management approach was elected, with plans to re-consider surgical
intervention if evidence of hematoma expansion, development of
hydrocephalus, or further neurologic decline occurred.
Over the next several days, the patient's neurologic exam
improved. Head CT on post-hemorrhage day 5 (Fig. 2) demonstrated
decreased mass effect in the posterior fossa, with stable to decreased
hematoma size.
The patient was extubated on hospital day 11 and discharged to an
inpatient rehabilitation facility on hospital day 15, without requiring
operative intervention during his hospital course. NIHSS at discharge
was 1 (ataxia) and Modiﬁed Rankin Scale was 1, which were both
stable at six-month clinic follow-up.
Conclusion
Several concerns exist regarding the initial trials conducted on
NOACs. One is that patients with any history of intracranial
hemorrhage (ICH), renal failure, active liver disease, or severeFig. 2. Head CT on post-hypertension were excluded [6,7]. Another concern is that there are
no head-to-head studies directly comparing NOACs. To date, there are
only indirect comparisons of the newer agents [8].
Perhaps the most worrisome evidentiary deﬁcit involves their
potential for hemorrhagic complications. While there are several
studies comparing the rates of warfarin- and NOAC-related ICH, [9,10]
there is no evidence comparing the respective clinical outcome or case
fatality in these two groups [11]. Furthermore, while several studies
claim superior cost-effectiveness of NOACs over warfarin, and
apixaban over other novel agents, these studies failed to include the
costs associated with ICH in the analyses [12,13].
Perhaps the most widely-toted advantage of the NOACs is their
predictable pharmacokinetics, obviating the need for routine labora-
tory monitoring [14]. In the outpatient setting, this is an advantage to
the patient and provider. However, in the bleeding trauma or
neurosurgery patient, the lack of a reliable assay is a potentially
fatal disadvantage.
The ﬁnal issue is the most germane to the current case discussion:
How can the effects of NOACs in the actively bleeding patient be
reversed? Currently we have, at best, Class III and IV evidence
supporting the use of various reversal strategies depending on the
anticoagulant on board. Historical reversal strategies (e.g. vitamin K
and fresh frozen plasma) are slow and have little impact on the effect
of NOACs [15]. Several authors have demonstrated the successful use
of emergent hemodialysis in patients on dabigatran. Unfortunately,hemorrhage day 5.
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latter two are highly protein bound [5]. Available alternative
strategies are those used in the current case: administration of
prothrombin complex concentrate (PCC) or their activated counter-
parts (aPCCs such as FEIBA). While this strategy appeared to work in
the current case, and while the plurality of the currently available
evidence supports the use of PCCs or aPCCs in this setting [4], there
are, to date, no guidelines or prospective studies to guide the
decision-making process regarding surgical intervention.
Despite positive evidence on their efﬁcacy, these concerns and the
lack of evidence on managing complications associated with NOACs
have ledmany authors to advise cautionwhen prescribing these agents.
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